Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
about
Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implicationsDaptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect")Daptomycin as a possible new treatment option for surgical management of Methicillin-Resistant Staphylococcus aureus sternal wound infection after cardiac surgery.Treatment of gram-positive deep sternal wound infections in cardiac surgery--experiences with daptomycin.Phenotypic and genotypic characterization of daptomycin-resistant methicillin-resistant Staphylococcus aureus strains: relative roles of mprF and dlt operonsFosfomycin plus β-Lactams as Synergistic Bactericidal Combinations for Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus aureus.Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significanceCausal role of single nucleotide polymorphisms within the mprF gene of Staphylococcus aureus in daptomycin resistancePre-clinical experience with daptomycin.Staphylococcus aureus inactivates daptomycin by releasing membrane phospholipids.Impact of High-Level Daptomycin Resistance in the Streptococcus mitis Group on Virulence and Survivability during Daptomycin Treatment in Experimental Infective Endocarditis.Phenotypic and genotypic correlates of daptomycin-resistant methicillin-susceptible Staphylococcus aureus clinical isolates.Early in vitro and in vivo development of high-level daptomycin resistance is common in mitis group Streptococci after exposure to daptomycin.Early in vitro development of daptomycin non-susceptibility in high-level aminoglycoside-resistant Enterococcus faecalis predicts the efficacy of the combination of high-dose daptomycin plus ampicillin in an in vivo model of experimental endocarditiComparative efficacies of tedizolid phosphate, vancomycin, and daptomycin in a rabbit model of methicillin-resistant Staphylococcus aureus endocarditis.Clinical pharmacological approach for balancing the use of daptomycin and linezolid in comparison with that of vancomycin in the treatment of MRSA-related infections.Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis.Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus.In Vivo Effects of Cefazolin, Daptomycin, and Nafcillin in Experimental Endocarditis with a Methicillin-Susceptible Staphylococcus aureus Strain Showing an Inoculum Effect against Cefazolin.Effect of vancomycin minimal inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus endocarditis.Daptomycin for treatment of methicillin-resistant Staphylococcus epidermidis saphenectomy wound infection after coronary artery bypass graft operation (CABG): a case report.Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus.The Combination of Daptomycin plus Fosfomycin has Synergistic, Potent and Rapid Bactericidal Activity against Methicillin-Resistant Staphylococcus aureus (MRSA) in a Rabbit Model of Experimental Endocarditis (EE).Characterization of genetic changes associated with daptomycin nonsusceptibility in Staphylococcus aureus.Effect of a Point Mutation in mprF on Susceptibility to Daptomycin, Vancomycin, and Oxacillin in an MRSA Clinical Strain.
P2860
Q24646677-9B2E5B2F-6E07-4B21-B660-2DBEB89F7634Q34045273-3138834B-8EDA-48FA-8DA0-C44D911E4616Q34067779-879DC342-93FD-41D0-AFC2-98B82E189C70Q35248216-A84DBB55-2BAB-45ED-A8D1-FC0DF811B35AQ35256159-4185925A-1B3E-4ED2-B1B7-75ADD146AF2DQ36439147-0893DA70-3582-4B32-87A1-FBB5626A550CQ36692468-711C55F4-809C-43C5-B801-E0B11D74D9E5Q37263514-D327D2D3-66DC-4265-B893-51D99ABBB9E7Q37284356-2FAE23C6-2BFF-42B0-8852-43AA546B34A6Q38404983-01A30F24-9B36-42BE-AFBE-B19D9C08A0B4Q38926289-AF976431-A2E5-4B89-9B16-7E6F8ECA8F26Q39000860-5AEDC9A3-E497-4AAA-AF90-AB389FED8A32Q40003948-685BB7EC-B51C-4938-929B-F118A5D64DC9Q40330828-1D989C49-B139-490B-8BF6-0A695C4C9465Q40675142-B3B1C9DB-F707-40BF-A36D-25A28AE0CCE2Q40845477-7A69B3D3-EC08-4495-A43E-5553DCE89AD1Q41874503-0A99CAEA-3B33-4C70-A3CD-CFC9876610F7Q42027484-4079885B-F950-41F7-A048-284986EB72B5Q42110143-BE5868E8-36CD-4276-9658-34AFC319C613Q42223222-72763ED4-C47B-44FC-BE75-3CDAD4DEDEEEQ42571140-EDDAAFF7-0399-40BE-A616-B7E051781499Q42586811-9E925FC8-5FAF-4C85-9F41-D239BD4BB045Q53699196-9D27C7C7-3BA0-46B7-B829-010B6E2F4C89Q55234569-717B8F0C-F11E-4AD5-90C6-8AD2796F3024Q55284617-17105BC2-2337-4446-A9C5-C2E12BA53B20
P2860
Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Daptomycin is effective in tre ...... mediate Staphylococcus aureus.
@ast
Daptomycin is effective in tre ...... mediate Staphylococcus aureus.
@en
type
label
Daptomycin is effective in tre ...... mediate Staphylococcus aureus.
@ast
Daptomycin is effective in tre ...... mediate Staphylococcus aureus.
@en
prefLabel
Daptomycin is effective in tre ...... mediate Staphylococcus aureus.
@ast
Daptomycin is effective in tre ...... mediate Staphylococcus aureus.
@en
P2093
P2860
P356
P1476
Daptomycin is effective in tre ...... mediate Staphylococcus aureus.
@en
P2093
Ana del Río
Asunción Moreno
Carlos A Mestres
Cristina García de la Mària
Dolors Soy
Eurídice Amat
Francesc Marco
Hospital Clinic Experimental Endocarditis Study Group
José M Gatell
José M Miró
P2860
P304
P356
10.1128/AAC.00510-07
P407
P577
2008-04-21T00:00:00Z